Loading...
XHKG
3320
Market cap3.43bUSD
Oct 08, Last price  
4.34HKD
1D
-0.69%
1Q
-3.38%
Jan 2017
-50.97%
IPO
-52.44%
Name

China Resources Pharmaceutical Group Ltd

Chart & performance

D1W1MN
XHKG:3320 chart
P/E
6.06
P/S
0.09
EPS
0.72
Div yield, %
3.14%
Shrs. gr., 5y
—
Rev. gr., 5y
8.40%
Revenues
300.01b
+9.42%
116,950,696,000135,749,180,000146,568,105,000156,705,203,000172,532,204,000189,689,107,000204,453,869,000200,423,023,000236,806,169,000254,106,366,000270,397,302,000274,182,490,000300,013,084,000
Net income
4.50b
+26.27%
2,639,517,0002,645,940,0002,850,076,0002,821,410,0003,483,036,0004,037,890,0003,286,419,0002,778,656,0003,080,673,0003,500,270,0003,854,247,0003,565,548,0004,502,259,000
CFO
22.78b
+29.91%
4,102,157,0003,347,871,8085,988,790,0004,119,647,0004,857,538,0008,246,965,0005,254,057,0006,277,176,00011,220,436,00010,898,714,00015,549,886,00017,535,514,00022,779,919,000
Dividend
Sep 10, 20260.1006 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

Key people

Xiaosong Bai
Executive Chairman of the Board · since 2024
Chairman of Jiangzhong Pharmaceutical · since 2022
Wenchao Lu
Chairman of CR Double-Crane · since 2023
Chairman of CR Sanjiu · since 2024
Director and President of CR Sanjiu, Chairman of KPC Pharmaceuticals Inc · since 2024
Jianjun Wu
Chairman of CR Pharmaceutical Commercial · since 2023
Xingpin Cui
Vice President · since 2021
Kai Qiu
Vice President · since 2023
President, Executive Director · since 2025
Ronghui Deng
Chief Financial Officer, Executive Director · since 2023
Changan Liu
Executive Director · since 2025
Yipeng Liu
Secretary of the Discipline Inspection Commission · since 2023
Wei Guo
Non-Executive Director · since 2023
Chuan Guo
Non-Executive Director · since 2024
Ruifang Jiao
Non-Executive Director · since 2022
Yongqiang Sun
Non-Executive Director · since 2023
Yuhang Wang
Non-Executive Director · since 2025
Mun Wai Chiu
Independent Non-Executive Director · since 2025
Independent Non-Executive Director · since 2016
Kin Fun Kwok
Independent Non-Executive Director · since 2016
IPO date
Oct 28, 2016
Employees
71,000
Domiciled in
HK
Incorporated in
HK
Headquarters & legal address
華潤大廈41樓04-05室
香港 999077
HK
Address
4104-05, 41/F, China Resources Building
26 Harbour Rd 999077
HK
Other language
China Resources Pharmaceutical Group Limited

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT